151,280 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Acquired by Kennondale Capital Management LLC

Kennondale Capital Management LLC acquired a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 151,280 shares of the biotechnology company’s stock, valued at approximately $755,000. Kennondale Capital Management LLC owned about 0.25% of Aldeyra Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp boosted its stake in Aldeyra Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after acquiring an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Aldeyra Therapeutics by 163.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after acquiring an additional 295,864 shares during the last quarter. Barclays PLC lifted its stake in Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after buying an additional 48,313 shares in the last quarter. SG Americas Securities LLC lifted its stake in Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 2,822 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in Aldeyra Therapeutics in the fourth quarter valued at approximately $234,000. Institutional investors own 59.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Monday, March 3rd.

Aldeyra Therapeutics Trading Down 8.7 %

Shares of ALDX opened at $6.31 on Tuesday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics, Inc has a twelve month low of $2.75 and a twelve month high of $7.20. The firm’s 50 day moving average price is $5.81 and its two-hundred day moving average price is $5.48.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). As a group, research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.